This volume provides a comprehensive overview of recent advances in
targeting glutamate signaling for the treatment of major
psychiatric and neurological disorders. It draws on the latest
findings in glutamate neurobiology and offers valuable insights
into the application of translational principles in neuroscience
drug discovery and development. In each chapter, glutamate as a
neurotransmitter, its receptors and transporters, and their
interplay with other neurotransmitters and neurotrophic factors,
are discussed in the context of a specific, highly prevalent and
disabling CNS disease. Most recent and detailed information is
provided on Ischemic Stroke, Chronic Stress, Major Depressive
Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD),
Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia,
Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD),
Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple
Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity
Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders.
Moreover, the book includes an extensive overview of glutamatergic
treatments already available on the market, and those which are
currently in pharmaceutical drug development pipelines. The
primary beneficiaries will be neurology and psychiatry specialists
and residents, neuroscientists, neuropharmacologists,
pharmaceutical industry and clinical research organization
professionals, academics, and clinicians working with psychiatric
and neurological patients with comorbidities such as cardiologists,
pulmonologists, and endocrinologists. This book will also appeal to
psychiatry and neurology subspecialists and clinicians working in
neuroscience labs seeking an easy-to-understand yet comprehensive
overview of contemporary evidence-based clinical insights backed by
basic science (preclinical) research evidence. Given its scope, the
book is also a unique and indispensable resource for both
preclinical and clinical neuroscientists, medical advisors, and
clinical research specialists in the pharmaceutical industry. In
addition, it will appeal to neuroscience and
neuropsychopharmacology students and guide them through the
complexities of glutamate involvement in the pathophysiology of the
most common debilitating brain diseases with high unmet medical
needs.
General
Imprint: |
Springer Nature Switzerland AG
|
Country of origin: |
Switzerland |
Release date: |
April 2023 |
First published: |
2022 |
Editors: |
Zoran M. Pavlovic
|
Dimensions: |
235 x 155mm (L x W) |
Pages: |
600 |
Edition: |
1st ed. 2022 |
ISBN-13: |
978-3-03-087482-7 |
Categories: |
Books
|
LSN: |
3-03-087482-6 |
Barcode: |
9783030874827 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!